logo

ORMP

Oramed·NASDAQ
--
--(--)
--
--(--)
3.47 / 10
Netural

Fundamental analysis rates ORMP poorly at 3.5/10. Key positives include a solid interest coverage ratio (15.48) and strong revenue growth (92.66% YoY). Drawbacks are a high days sales outstanding (72.55) and an unfavorable PB-ROE divergence (-0.56). Composite factors like profit-to-market value (2.89) and asset-to-market value (-0.50) provide some balance, but the overall picture leans defensive, indicating limited upside without improvement in current ratios and collection efficiency.

Fundamental(3.47)SentimentTechnical

Analysis Checks(7/10)

Revenue-MV
Value-0.26
Score1/3
Weight7.78%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value78.47
Score2/3
Weight1.66%
1M Return1.11%
Days sales outstanding
Value72.55
Score1/3
Weight-2.13%
1M Return-1.57%
Profit-MV
Value2.89
Score2/3
Weight15.46%
1M Return8.45%
Net income-Revenue
Value4.55
Score2/3
Weight15.47%
1M Return8.45%
PB-ROE
Value-0.56
Score1/3
Weight18.82%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.55%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value92.66
Score2/3
Weight0.64%
1M Return0.43%
Asset-MV
Value-0.50
Score3/3
Weight28.66%
1M Return13.15%
Cash-MV
Value-0.07
Score2/3
Weight15.20%
1M Return8.41%
Is ORMP fundamentally strong?
  • ORMP scores 3.47/10 on fundamentals and holds a Fair valuation at present. Backed by its 31.09% ROE, 0.00% net margin, 3.19 P/E ratio, 0.69 P/B ratio, and 845.45% earnings growth, these metrics solidify its Netural investment rating.